The European Commission granted marketing authorization to Amgen and UCB for Evenity (romosozumab) for treating severe osteoporosis in postmenopausal women at high risk of fracture.

For Breast Cancer Awareness Month, BioSpace gathered examples of recent breakthroughs in breast cancer treatment.

Novartis’ Phase III MONALEESA-3 clinical trial of Kisqali (ribociclib) hit the key secondary endpoint, overall survival.

Cuts implemented by Israel-based Teva Pharmaceutical hit the shores of the United States. The company is laying off 208 people in the Philadelphia area.

The FDA approved Mylan’s Estradiol Vaginal Cream USP 0.01%, the first generic version of Allergan’s Estrace.

Astellas Pharma struck a deal valued at up to $853 million to acquire Belgium-based Ogeda SA, a privately held clinical-stage drug discovery company, and its lead drug candidate fezolinetant.

November 18, 2015By Mark Terry, BioSpace.com Breaking News Staff   Waltham, Mass.-based Radius Health, Inc. (RDUS), announced yesterday that it has sent a Marketing Authorization Application (MAA) to European regulatory agencies for its abaloparatide-SC for postmenopausal osteoporosis. At the same time, the company indicated that it is delaying its New Drug Application (NDA) to the […]

Amgen Inc said its experimental bone drug was found to be more effective than an already marketed drug in a late-stage study. Amgen’s drug, romosozumab, met the main goal of showing a significant difference over Eli Lilly & Co’s teriparatide in improving total hip bone density by the 12th month in postmenopausal women with osteoporosis. […]

Women who have pregnancies less than a year apart may have a greater risk for osteoporosis later in life than those who wait longer between babies, a study suggests. Researchers compared the reproductive histories of 239 postmenopausal women with osteoporosis to 298 similar women without thinning bones. Pregnancies no more than 12 months apart were […]